Overview

Study of BMS-986012 in Subjects With Small Cell Lung Caner

Status:
Completed
Trial end date:
2017-08-29
Target enrollment:
Participant gender:
Summary
A study to evaluate safety and tolerability of BMS-986012 in patients with small cell lung cancer
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Cisplatin
Etoposide
Etoposide phosphate